Becton, Dickinson and Company(BDX)
NYSE
$216.08
0.66 (0.31%)

Becton, Dickinson and Company(BDX)Company Profile & Business
NYSE

Company Profile

Business overview, scale, and footprint

Company NameBecton, Dickinson and Company
Ticker SymbolBDX
ExchangeNYQ
SectorHealthcare
IndustryMedical Instruments & Supplies
Employees60,000
CEOMr. Thomas E. Polen Jr.
Founded1897
HeadquartersFranklin Lakes, NJ, United States
CountryUnited States
Websitebd.com
Next Earnings DateN/A

Business Overview

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Insider Transactions

Open-market purchases and sales reported on SEC Form 4

Insider Activity Summary

Between Feb 18, 2026 and Nov 5, 2026, insiders of Becton, Dickinson and Company (BDX) reported 22 open-market trades on SEC Form 4: 0 purchases (0 shares) and 22 sales (28,773 shares, about $4.99M). Sales exceeded purchases by about $4.99M.

22 open-market insider trades found. Showing 10 of 22.

Show:entries
Insider NameRelation to CompanyShares ChangedPriceTransaction Date
Polen Thomas E JrChairman, CEO and President-2,993$210.00Nov 5, 2026
Feld MichaelEVP, Chief Revenue Officer-76$198.13Oct 26, 2026
Feld MichaelEVP, Chief Revenue Officer-76$183.70Sep 28, 2026
Feld MichaelEVP, Chief Revenue Officer-165$188.49Aug 26, 2026
Polen Thomas E JrChairman, CEO and President-4,152$185.00Aug 13, 2026
Unknown InsiderChairman, CEO and President-4,152$185.00Aug 13, 2026
Goette RolandEVP and President, EMEA-2,438$180.84Aug 11, 2026
Unknown InsiderEVP and President, EMEA-2,438$180.84Aug 11, 2026
Feld MichaelEVP, Chief Revenue Officer-75$157.13Jul 27, 2026
Feld MichaelEVP, Chief Revenue Officer-75$152.80Jun 26, 2026
Page 1 of 3 (22 total transactions)